Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026

In this study we investigated the in vitro time dependence of radiosensitisation, pharmacokinetics and metabolism of NU7026, a novel inhibitor of the DNA repair enzyme DNA-dependent protein kinase (DNA-PK). At a dose of 10 μ M , which is nontoxic to cells per se , a minimum NU7026 exposure of 4 h i...

Full description

Saved in:

Bibliographic Details
Published in:	British journal of cancer Vol. 93; no. 9; pp. 1011 - 1018
Main Authors:	Nutley, B P, Smith, N F, Hayes, A, Kelland, L R, Brunton, L, Golding, B T, Smith, G C M, Martin, N M B, Workman, P, Raynaud, F I
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 31.10.2005 Nature Publishing Group
Subjects:	Animals Ataxia Biological and medical sciences Biological Availability Biomedical and Life Sciences Biomedicine Cancer Research Cancer therapies Cell Proliferation - drug effects Cell Proliferation - radiation effects Chromones - metabolism Chromones - pharmacokinetics DNA repair DNA-Activated Protein Kinase - antagonists & inhibitors Drug Evaluation, Preclinical Drug Resistance Enzyme Inhibitors - metabolism Enzyme Inhibitors - pharmacokinetics Enzymes Epidemiology Female Gamma Rays Humans Kinases Medical research Medical sciences Metabolism Metabolites Mice Mice, Inbred BALB C Molecular Medicine Morpholines - metabolism Morpholines - pharmacokinetics Oncology Ovarian Neoplasms - metabolism Ovarian Neoplasms - radiotherapy Pharmacokinetics Proteins Radiation Radiation Tolerance Translational Therapeutics Tumor Stem Cell Assay Tumors United Kingdom > UK pharmacokinetics metabolism DNA-PK NU7026 Cancerology DNA Inhibitor Metabolism Pharmacokinetics
ISSN:	0007-0920, 1532-1827
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!